TCRX
Tscan Therapeutics Inc
0.3205$
+0.9%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Tscan Therapeutics Inc (TCRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -28 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.1 | 15 | -5.8 | -7.4 | -10.0 | -11 | -14 | -14 | -20 | -13 | -17 | -16 | -24 | -22 | 8.0 | -24 | -29 | -26 | -28 | -27 | -38 | -33 | -32 | -32 | -24 | -28 | -116 | |
| 0.2 | 0.3 | 0.3 | 0.4 | 0.5 | 0.7 | 1.1 | 1.1 | 1.2 | 1.2 | 1.3 | 1.5 | 1.5 | 1.3 | 1.3 | 1.3 | 1.3 | 1.1 | 1.0 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.7 | 0.7 | 2.9 | |
| 0.1 | 0.1 | 0.1 | 0.2 | 0.3 | 0.5 | 0.9 | 0.8 | 1.0 | 1.0 | 1.2 | 1.3 | 1.1 | 1.2 | 1.3 | 1.5 | 2.0 | 2.3 | 2.5 | 2.7 | 3.4 | 3.3 | 3.0 | 2.0 | 2.5 | 2.4 | 9.8 | |
| 0.1 | 0.1 | 0.1 | – | 0.3 | 0.5 | 0.9 | 0.8 | 1.0 | 1.0 | 1.3 | 1.5 | 1.1 | 1.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.1 | 20 | 0.9 | -0.1 | -2.9 | -1.2 | 0.3 | -2.1 | -6.1 | -0.5 | -3.3 | -0.3 | -3.9 | -0.7 | 28 | -6.2 | -2.1 | 2.2 | -0.3 | 5.3 | -6.4 | 0.4 | -0.4 | -12 | 1.1 | -0.5 | -12 | |
| 1.2 | 0.3 | 1.3 | 1.4 | 3.0 | 3.9 | 0.9 | 2.2 | 0.5 | 1.9 | 0.4 | 1.4 | 0.8 | 0.4 | 1.4 | 0.5 | 0.7 | 0.9 | 1.4 | 0.9 | 1.5 | 1.3 | 1.4 | 0.2 | 0.1 | 0.5 | 2.2 | |
| -1.2 | -0.3 | -1.3 | -1.4 | -3.0 | -3.9 | -0.9 | -2.2 | -0.5 | -1.9 | -0.4 | -1.4 | -0.8 | -0.4 | -61 | 1.9 | 36 | -34 | -82 | 27 | 14 | 48 | 33 | 15 | -0.1 | -0.5 | 47 | |
| 0.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -2.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | -0.2 | 0.2 | – | – | – | 0.3 | – | 0.2 | – | 0.1 | – | 0.1 | – | |
| – | – | – | – | – | – | – | 29 | 29 | 29 | 29 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.2 | 0.0 | 0.0 | 0.0 | 100 | -0.7 | 91 | 0.1 | 0.1 | 0.0 | 29 | 0.1 | 136 | 136 | -0.3 | 0.0 | 0.3 | 162 | 1.2 | 46 | -0.5 | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.2 | |
| -6.1 | 15 | -7.1 | -8.7 | 87 | -15 | 76 | -21 | -21 | -15 | 12 | -17 | -24 | 113 | -54 | -22 | 7.2 | 102 | -109 | 46 | -25 | 15 | 0.1 | -17 | -24 | -28 | -69 | |
| -6.3 | 15 | -7.1 | -8.7 | -13 | -15 | -14 | -17 | -21 | -15 | -17 | -17 | -24 | -22 | 6.6 | -24 | -30 | -27 | -29 | -28 | -39 | -35 | -34 | -32 | -24 | -28 | -118 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.